GlobeNewswire: Advanced Accelerator Applications Contains the last 10 of 66 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:20:13ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/02/07/1712027/0/en/Advanced-Accelerator-Applications-Announces-Health-Canada-Approval-for-Lutathera-a-Treatment-for-Gastroenteropancreatic-Neuroendocrine-Tumors-GEP-NETs.html?f=22&fvtc=4&fvtv=27892Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)¹2019-02-07T12:00:00Z<![CDATA[SAINT-GENIS-POUILLY, France, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (AAA), a Novartis company and leader in nuclear medicine theragnostics, today announced that Health Canada has approved Lutathera™ (lutetium (177Lu) oxodotreotide) for the treatment of unresectable (not removable by surgery) or metastatic, well-differentiated, somatostatin receptor-positive (expressing the somatostatin receptor) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults with progressive disease1.]]>https://www.globenewswire.com/news-release/2018/12/03/1660509/0/en/Advanced-Accelerator-Applications-signs-exclusive-option-and-license-agreement-with-FUJIFILM-Toyama-Chemical-to-develop-and-commercialize-radiolabeled-FF-10158-for-oncology-indicat.html?f=22&fvtc=4&fvtv=27892Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications2018-12-03T08:00:00Z<![CDATA[SAINT-GENIS-POUILLY, France, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (AAA), a Novartis company and leader in nuclear medicine theragnostics, today announced that it has entered into an exclusive option and license agreement with FUJIFILM Toyama Chemical, a leading radiopharmaceutical company in Japan, to develop and commercialize radiolabeled FF-10158 for oncology indications. Under the terms of the agreement, AAA is granted worldwide rights to FF-10158, with the exception of Japan, in exchange for an upfront payment and future milestones and royalties.]]>https://www.globenewswire.com/news-release/2018/02/12/1338914/0/en/Advanced-Accelerator-Applications-Signs-Exclusive-License-Agreement-with-Cancer-Targeted-Technology-to-Develop-CTT1057-an-F-18-Labeled-PSMA-Ligand-for-Diagnostic-Applications-in-Pr.html?f=22&fvtc=4&fvtv=27892Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer2018-02-12T12:00:00Z<![CDATA[SAINT-GENIS-POUILLY, France, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a Novartis company and leader in nuclear medicine theragnostics, today announced that it has entered into an exclusive worldwide license agreement with Cancer Targeted Technology, LLC (CTT) to develop and market an investigational new drug product, F-18-labeled CTT1057. CTT1057 is a ligand of Prostate-Specific Membrane Antigen (PSMA) for Positron Emission Tomography (PET) imaging of prostate cancer.]]>https://www.globenewswire.com/news-release/2018/02/01/1330403/0/en/Advanced-Accelerator-Applications-Announces-Completion-of-Subsequent-Offering-Period-for-Novartis-Tender-Offer.html?f=22&fvtc=4&fvtv=27892Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer2018-02-01T21:05:00Z<![CDATA[SAINT-GENIS-POUILLY, France, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), a Novartis company and a leader in nuclear medicine theragnostics, today announced that a subsidiary of Novartis AG (NYSE:NVS) (“Novartis”), Novartis Groupe France S.A. (“Purchaser”), has completed the subsequent offering period of the tender offer to purchase all of the outstanding ordinary shares (“Ordinary Shares”), including Ordinary Shares represented by American Depositary Shares (“ADSs”), of AAA for a price of USD 41.00 per Ordinary Share and USD 82.00 per ADS, in each case, payable net to the seller in cash, without interest (the “Offer”). The subsequent offering period for the Offer, which commenced on January 22, 2018, expired as scheduled at 12:00 midnight, New York City time, on January 31, 2018. According to Novartis, The Bank of New York Mellon, as ADS tender agent for the Offer, and Banque Transatlantique S.A., as Ordinary Shares agent for the Offer, have advised that, as of the expiration of the subsequent offering period, 95,127,753 Ordinary Shares (including Ordinary Shares represented by ADSs) were validly tendered during the initial offering period and the subsequent offering period taken together, representing approximately 98.7% of all outstanding Ordinary Shares (including Ordinary Shares represented by ADSs). Purchaser has accepted for payment and has promptly paid (or will promptly pay) for all Ordinary Shares and ADSs validly tendered during the subsequent offering period.]]>https://www.globenewswire.com/news-release/2018/01/26/1313140/0/en/Advanced-Accelerator-Applications-Receives-US-FDA-Approval-for-LUTATHERA-for-Treatment-of-Gastroenteropancreatic-Neuroendocrine-Tumors.html?f=22&fvtc=4&fvtv=27892Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors2018-01-26T17:00:04Z<![CDATA[First-in-class Therapy Demonstrated 79% Improvement in Progression Free Survival in NETTER-1 Phase 3 Study in Midgut NET Patients]]>Lutathera (lutetium Lu 177 dotatate) vial pictureLutathera (lutetium Lu 177 dotatate) vial picturePFS graphicPFS graphic Lutathera (lutetium Lu 177 dotatate) mechanism of action pictureMechanism of action cartoonhttps://www.globenewswire.com/news-release/2018/01/26/1313140/0/en/Advanced-Accelerator-Applications-Receives-US-FDA-Approval-for-LUTATHERA-for-Treatment-of-Gastroenteropancreatic-Neuroendocrine-Tumors.htmlLutathera (lutetium Lu 177 dotatate) mechanism of action videoLutathera (lutetium Lu 177 dotatate) mechanism of action videohttps://www.globenewswire.com/news-release/2018/01/22/1298427/0/en/Advanced-Accelerator-Applications-Announces-Completion-of-3-9-Billion-Novartis-Tender-Offer.html?f=22&fvtc=4&fvtv=27892Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer2018-01-22T13:00:00Z<![CDATA[Novartis Global Oncology Expertise to Enhance Launch of Lutetium Lu 177 Dotatate (LUTATHERA®) and Accelerate Development of Theragnostic Pipeline Novartis Global Oncology Expertise to Enhance Launch of Lutetium Lu 177 Dotatate (LUTATHERA®) and Accelerate Development of Theragnostic Pipeline]]>https://www.globenewswire.com/news-release/2017/12/07/1247346/0/en/Advanced-Accelerator-Applications-Announces-Commencement-of-Novartis-Tender-Offer.html?f=22&fvtc=4&fvtv=27892Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer2017-12-07T12:00:00Z<![CDATA[SAINT-GENIS-POUILLY, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that a direct and indirect subsidiary of Novartis AG (NYSE:NVS), Novartis Groupe France S.A., a société anonyme organized under the laws of France (“Purchaser”), has commenced a cash tender offer to purchase all of the outstanding ordinary shares, nominal value €0.10 per share (each, an “Ordinary Share,” and collectively, the “Ordinary Shares”), including Ordinary Shares represented by American Depositary Shares (each of which represents two Ordinary Shares) (each, an “ADS,” and collectively, the “ADSs,” and, together with the Ordinary Shares, the “Company Shares”), of AAA, for a price of US $41.00 per Ordinary Share and US $82.00 per ADS, in each case, payable net to the seller thereof in cash, without interest, less any withholding taxes that may be applicable (the “Offer”). The Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated December 7, 2017 (the “Offer to Purchase”), the accompanying Ordinary Share Acceptance Form and ADS Letter of Transmittal, and pursuant to the terms of the previously announced Memorandum of Understanding, dated as of October 28, 2017, by and between Novartis and AAA, as amended on December 5, 2017 (the “MoU”).]]>https://www.globenewswire.com/news-release/2017/12/05/1229443/0/en/Advanced-Accelerator-Applications-Board-of-Directors-Recommends-3-9-Billion-All-Cash-Tender-Offer-by-Novartis.html?f=22&fvtc=4&fvtv=27892 Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis2017-12-05T21:00:00Z<![CDATA[SAINT-GENIS-POUILLY, France, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that its Board of Directors, following the completion of the information and consultation of the Company’s works council, has (i) determined that the transactions contemplated in the Memorandum of Understanding entered into with Novartis AG (NYSE:NVS) on October 28, 2017 (the “Memorandum of Understanding”), including the cash tender offer described in the subsequent paragraph, are (x) consistent with and will further the business objectives and goals of the Company, (y) advisable and (z) in the best interests of the Company, its stockholders, other stakeholders and its employees, (ii) approved and adopted the transactions contemplated by the Memorandum of Understanding and (iii) determined to recommend that the Company’s stockholders support the offer, accept the offer and tender their shares in the offer.]]>https://www.globenewswire.com/news-release/2017/11/17/1194805/0/en/Advanced-Accelerator-Applications-Reports-39-Sales-Growth-for-Third-Quarter-2017.html?f=22&fvtc=4&fvtv=27892Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 20172017-11-17T12:39:18Z<![CDATA[$3.9 Billion All Cash Proposed Tender Offer by Novartis]]>https://www.globenewswire.com/news-release/2017/10/30/1159659/0/en/Advanced-Accelerator-Applications-Announces-3-9-Billion-All-Cash-Proposed-Tender-Offer-by-Novartis.html?f=22&fvtc=4&fvtv=27892Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis2017-10-30T06:00:00Z<![CDATA[Novartis Oncology Expertise to Facilitate Ongoing Development of Theragnostic Pipeline Novartis Oncology Expertise to Facilitate Ongoing Development of Theragnostic Pipeline]]>